The U.S. Court of Appeals for the Federal Circuit (CAFC) has reversed a district court decision finding certain claims of two patents covering prenatal DNA testing patent ineligible. The CAFC held that “the claimed methods utilize the natural phenomenon that the inventors discovered by employing physical process steps” and thus were patent-eligible. The patents at issue in the case acknowledge but are not related to the patented invention held invalid in Ariosa Diagnostics, Inc. v. Sequenom, Inc., 788 F.3d 1371, 1373 (Fed. Cir. 2015). The opinion was authored by Judge Lourie, with Judge Reyna dissenting.
CAFC Holds Sequenom’s Prenatal DNA Patent Claims Eligible Under 101
No Comments
Litigation
- Justices Lean Toward Limiting, Not Eliminating, Assignor Estoppel Doctrine in Minerva v. Hologic
- EPO Opposition Division Upholds NuCana Patent on Gilead’s Sovaldi, Highlighting Potential Flaws of CAFC Ruling in Gilead/Idenix
- NetSoc Appeals to SCOTUS, Claiming Improper Analysis of Social Network Patent Nixed Under 101
- The View from the Court’s 2 Live Crew: Examining the Thomas/Alito Dissent in Google v. Oracle
- Tillis, Michel and Iancu Back Ericsson in Heated International FRAND Dispute with Samsung
Recent Posts
- Justices Lean Toward Limiting, Not Eliminating, Assignor Estoppel Doctrine in Minerva v. Hologic
- Kappos at PTAB Masters Day 2: PTAB Problems Arose When It Failed to Evolve
- EPO Opposition Division Upholds NuCana Patent on Gilead’s Sovaldi, Highlighting Potential Flaws of CAFC Ruling in Gilead/Idenix
- Countries Like the Philippines are Unable to Utilize IP Flexibilities to Fight COVID-19
- Why the Patent Classification System Needs an Update